"extensive comorbidities with severely limited survival (e.g. < 1 year)"
"The typical indication of cardiac resynchronisation therapy is the improvement of cardiac haemodynamics and symptoms in heart failure with left ventricular dysfunction to prevent hospitalisation and reduce mortality, especially in the setting of left bundle branch block (LBBB) and/or cardiac dyssynchrony 1-5. According to the European Society of Cardiology (ESC Guidelines 2021), this includes symptomatic patients (NYHA class II, III and IV) with heart failure with reduced ejection fraction (LVEF"
"The typical indication of cardiac resynchronisation therapy is the improvement of cardiac haemodynamics and symptoms in heart failure with left ventricular dysfunction to prevent hospitalisation and reduce mortality, especially in the setting of left bundle branch block (LBBB) and/or cardiac dyssynchrony 1-5. According to the European Society of Cardiology (ESC Guidelines 2021), this includes symptomatic patients (NYHA class II, III and IV) with heart failure with reduced ejection fraction (LVEF"
"LBBB morphology and QRS ≥150 ms (I)"
"LBBB morphology and QRS 130-149 ms (IIa)"
"non-LBBB morphology and QRS ≥150 ms (IIa)"
"Contraindications to cardiac resynchronization therapy are heart failure with QRS"
"non-left bundle branch block patterns with a QRS"
"non-left bundle branch block QRS morphology such as right bundle branch block"
Expected headings
"Radiographic features"
"Plain radiograph"
"Ultrasound"
"Echocardiography"
"CT"
"MRI"
"Radiology report"
"The typical indication of cardiac resynchronisation therapy is the improvement of cardiac haemodynamics and symptoms in heart failure with left ventricular dysfunction to prevent hospitalisation and reduce mortality, especially in the setting of left bundle branch block (LBBB) and/or cardiac dyssynchrony 1-5. According to the European Society of Cardiology (ESC Guidelines 2021), this includes symptomatic patients (NYHA class II, III and IV) with heart failure with reduced ejection fraction (LVEF"
"venous access via axillary, cephalic or subclavian veins"
"extensive comorbidities with severely limited survival (e.g. < 1 year)"